Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease
NCT06263478Phase 3Active, not recruiting
- Sponsor
- Incyte
- Start
- Jul 2024
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of axatilimab in chronic graft-versus-host disease (cGVHD), sponsored by Incyte. Primary endpoint: Overall Response Rate at 168 days. Started Jul 2024; status: active, not recruiting.
02
Drugs
axatilimab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06263478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06263478.